Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | RAB9A | P51151 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | CASP3 | P42574 | 1/20 | 0.66 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.66 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.66 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.66 |
| ▸ | SNCA | P37840 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | P4HB | P07237 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4461037 | 1.00 | MAPT (0.66) | MAPTMEN1ALDH1A1LMNARAB9A | |
| SCHEMBL9338057 | 0.89 | PTGS2 (0.67) | MAPTMEN1ALDH1A1LMNARAB9A | |
| SCHEMBL9338034 | 0.89 | PTGS2 (0.67) | MAPTMEN1ALDH1A1LMNARAB9A | |
| SCHEMBL9341891 | 0.87 | MAPT (0.71) | MAPTMEN1ALDH1A1LMNARAB9A | |
| SCHEMBL30039604 | 0.87 | MAPT (0.71) | MAPTMEN1ALDH1A1LMNARAB9A | |
| SCHEMBL9341898 | 0.87 | MAPT (0.71) | MAPTMEN1ALDH1A1LMNARAB9A | |
| SCHEMBL28600841 | 0.85 | MAPT (0.68) | MAPTMEN1ALDH1A1LMNARAB9A | |
| SCHEMBL9341822 | 0.85 | MAPT (0.62) | MAPTMEN1ALDH1A1LMNARAB9A | |
| SCHEMBL9341829 | 0.85 | MAPT (0.62) | MAPTMEN1ALDH1A1LMNARAB9A | |
| SCHEMBL25204032 | 0.84 | MAPT (0.66) | MAPTMEN1ALDH1A1LMNARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1701938-B1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | GENFIT (FR) | 2012-07-25 | — | — | EP | claimed |
| US-20080058412-A1 | 1,3-Diphenylprop-2-En-1-One Derivative Compounds, Preparation Method Thereof and Uses of Same | GENFIT (FR) | 2008-03-06 | — | — | US | claimed |
| JP-2007517841-A | — | — | 2007-07-05 | — | — | JP | claimed |
| EP-1701938-A1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | Genfit (FR) | 2006-09-20 | — | — | EP | claimed |
| WO-2005073184-A1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | GENFIT (FR) | 2005-08-11 | — | — | WO | claimed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2024233598-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2024-11-14 | — | — | WO | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| EP-1701938-B1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | GENFIT (FR) | 2012-07-25 | — | — | EP | disclosed |
| US-7547729-B2 | 1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same | GENFIT (FR) | 2009-06-16 | — | — | US | disclosed |
| US-20080058412-A1 | 1,3-Diphenylprop-2-En-1-One Derivative Compounds, Preparation Method Thereof and Uses of Same | GENFIT (FR) | 2008-03-06 | — | — | US | disclosed |
| EP-1701938-A1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | Genfit (FR) | 2006-09-20 | — | — | EP | disclosed |
| WO-2005073184-A1 | 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVE COMPOUNDS, PREPARATION METHOD THEREOF AND USES OF SAME | GENFIT (FR) | 2005-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058412-A1 | 1,3-Diphenylprop-2-En-1-One Derivative Compounds, Preparation Method Thereof and Uses of Same | TYR, DHPS, DDT | MAPT 2537/4885MEN1 1140/4885ALDH1A1 7/4885 |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | MAPT 3297/4885MEN1 3367/4885ALDH1A1 3285/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885MEN1 2457/4885ALDH1A1 3081/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | MAPT 3512/4885MEN1 2457/4885ALDH1A1 3081/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.